- 15% Glycolic Acid corrects the visible signs of photoaging
- Hydrates dry, rough skin
- Targets enlarged pores, dullness, and rough texture
- For experienced Alpha Hydroxy Acid (AHA) users with normal to dry, non-sensitive skin
This powerful cream for normal to dry photodamaged skin is ideal for experienced Alpha Hydroxy Acid (AHA) users who want to step up to a more potent moisturizer. Face Cream Plus targets the visible signs of aging and normalizes the surface texture of rough, dry skin.
Recommended for those not sensitive to Glycolic Acid. Dye-Free. Paba-Free. Formulated with 15% Glycolic Acid.
Recommended Usage: Daily AM under sunscreen, and PM as tolerated
Key Ingredients: Glycolic Acid, Meadowfoam Seed Oil
Size: 1.4 oz. tube
Founded by Drs. Eugene Van Scott and Ruey Yu, internationally recognized for making the ground breaking discovery that Alpha Hydroxy Acids (AHAs) have profound beneficial effects on human skin, NeoStrata has a storied history of monumental breakthroughs in antiaging skincare. Since this initial discovery, NeoStrata has accelerated its research and commercialization efforts to develop a robust portfolio of novel technology to drive ongoing innovation.
Evolution of Hydroxy Acid Skincare
- 1st Generation: AHAs (Glycolic Acid, Citric Acid)
- 2nd Generation: PHAs (Gluconolactone)
- 3rd Generation: Bionic PHAs (Lactobionic Acid, Maltobionic Acid)
- Gluconolactone – Polyhydroxy Acid (PHA) from glucose in corn
- Lactobionic Acid – Bionic Acid (BA) from milk sugar
- Maltobionic Acid – Bionic Acid derived from glucose in corn
The creators of NeoStrata Company, Inc., Drs. Eugene Van Scott and Ruey Yu are internationally recognized for making the ground breaking discovery that Alpha Hydroxy Acids (AHAs) have profound beneficial effects on human skin. They discovered that AHA compounds such as Glycolic Acid and Lactic Acid are beneficial both in the treatment of dermatological conditions, encouraging cell turnover, and in stimulating prematurely aged or damaged skin to rejuvenate itself, thereby revolutionizing the treatment of aging skin.
Doctors Van Scott and Yu began working together in 1968 at Temple University in Philadelphia, sharing a mutual interest in diseases of the skin. Since more than half of all skin problems are due to difficulties in shedding and forming the stratum corneum, the doctors were determined to find ways to positively influence the formation of new layers of the skin. This partnership has spanned five decades and still continues today.
During a study to evaluate the effects of natural, physiologic type substances on patients with ichthyosis, a rare disorder with severe scaly skin, Drs. Van Scott and Yu discovered that this class of compounds has a profound effect on the development, maturation, and turnover of both normal and diseased epidermal skin. They were elated when ichthyosis patients returned with normal appearing skin where these compounds were applied. They named the compounds alpha-hydroxyacids (AHAs) and filed for their first patent (US Patent No. 3,879,537), entitled Treatment of Ichthyosiform Dermatoses, dated April 22, 1975.
Resulting from this early work was the first AHA prescription topical lotion, called Lac-Hydrin®, which was licensed to and marketed by Westwood (a division of Bristol-Myers Squibb). Lac-Hydrin® was the best-selling prescription treatment for dry skin for more than 10 years. AHAs such as Glycolic Acid and Lactic Acid continue to be broadly used in numerous products that treat dry skin.
While the initial discoveries relating to the use of AHAs were therapeutic in nature, a monumental breakthrough in the mid-1980s caused a revolution in antiaging skincare. The continuing research and clinical experience of Drs. Van Scott and Yu revealed that AHAs are not only beneficial in the treatment of dermatological conditions, but are also effective in stimulating older damaged skin to rejuvenate itself. Avon’s Anew® in the early 1990s was the first cosmetic skincare product to license the antiaging benefits of AHAs, and numerous cosmetic and pharmaceutical companies followed suit.